Traws Pharma to resubmit TXM data package to UK MHRA in Q3 2026 for Phase 2a influenza challenge study

Traws Pharma, Inc.

Resubmission of updated toxicology data package to MHRA expected in Q3 2026.
Formal MHRA response anticipated within 30 days after resubmission.
Data package intended to enable Phase 2a human influenza Challenge study of tivoxavir marboxil (TXM).
TXM targets seasonal influenza prophylaxis; preclinical data showed broad in vitro efficacy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.